SEC
NKTR icon

Seven Eight Capital’s Nektar Therapeutics NKTR Stock Holding History

Seven Eight Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,133
Closed -$1.91M – 487
2017
Q4 		$1.91M Buy
+2,133
New +$1.26M 0.2% 190

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Seven Eight Capital's NKTR Position: Q1 2018 in Review

Seven Eight Capital sold out of Nektar Therapeutics (NKTR) in Q1 2018, closing a stake of 2,133 shares — an estimated $1.91M sold.

Seven Eight Capital first reported a position in NKTR in Q4 2017 and held it in 1 quarter. The position peaked at $1.91M in Q4 2017. 359 funds tracked by Wall St. Rank hold NKTR as of Q1 2018.

  • Seven Eight Capital reported no remaining Nektar Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Seven Eight Capital sold 2,133 Nektar Therapeutics shares in Q1 2018, an estimated $1.91M.
  • Seven Eight Capital first reported a position in Nektar Therapeutics in Q4 2017 and held it in 1 quarter.
  • Seven Eight Capital's Nektar Therapeutics position peaked at $1.91M in Q4 2017.
  • 359 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2018.

Based on Seven Eight Capital's 13F filing for Q1 2018, filed 14 May 2018.